Minerva Neurosciences Inc (NERV) - Revenue and Sales Volume
The Minerva Neurosciences (NERV) business model is subject to binary risks due to the concentration of resources on a single drug. The company's aggregate performance on the GURU.Markets chart shows a sideways trend, where the 0.00 level serves as a critical mark. The complexity of brain research and strict regulatory oversight create high barriers, yet the establishment of a closed medical circuit ties clinics to unique schizophrenia therapy protocols.
Analytical breakdowns for Minerva Neurosciences, Inc. (NERV)
- stock quotes and analyst forecast:
- market capitalization indicators:
- company book value details:
- debt obligations and liquidity statistics:
Debt to Capital Minerva Neurosciences|NERV - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Minerva Neurosciences Inc|NERV - Company Debts|Debt to Net Assets Ratio Minerva Neurosciences, Inc.|NERV - Company Long-Term Debt|Short-Term Debt Minerva Neurosciences|Interim Coverage Ratio minervaneurosciences.com
- earnings and valuation multiples indicators:
NERV - Net Profit|Future Profit Minerva Neurosciences|NERV - P/E Multiple|Market Cap to Projected Earnings minervaneurosciences.com|NERV - PEG Multiple|Company Value to EBITDA Minerva Neurosciences, Inc.|NERV - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Minerva Neurosciences|NERV - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months minervaneurosciences.com|NERV - Earnings growth in current year|Expected net earnings per share growth next year Minerva Neurosciences
- sales volume and revenue indicators:
Comprehensive company analysis:Minerva - NERV
Investors determine business resilience by analyzing the actual cash flow from core operations. This indicator captures daily revenue from product sales, measuring the issuer's actual liquidity and capitalization rates. For Minerva Neurosciences (NERV), this flow depends directly on the commercial success of roluperidone following FDA approval. An assessment of investment risks becomes possible by studying the dynamics of the company's operating sales revenue.
Analysis of competing companies
Company Revenue BIIB|Revenue and Sales Volume NBIX|Revenue and Sales Volume regencellbioscience.com (RGC)|Axsome Therapeutics, Inc. - Company Sales|Company Sales Revenue ACAD|XENE - Company Revenue|VKTX (Viking Therapeutics Corp) - Company Sales Volume|SUPN: Revenue and Sales Volume|Company Total Revenue catalystpharma.com (CPRX)|Company Sales DNLI|Revenue and Sales Volume Harmony Biosciences Inc|Company Revenue Biohaven Pharmaceutical (BHVN)|AMLX (Amylyx Corp) - Company Sales Revenue|Company Revenue Trevi Therapeutics TRVI|praxismedicines.com (PRAX) - Company Total Revenue|AVXL - Company Revenue|Company Gross Revenue CeriBell Inc CBLL|PRTA: Revenue and Sales Volume|Company Sales Alector|ANNX (Annexon, Inc.) - Revenue and Sales Volume|Omeros Corp. (OMER) - Company Gross Revenue|Revenue and Sales Volume NGNE|ACIU - Company Total Revenue|Company Revenue Voyager Pharma VYGR|NMRA: Company Sales Volume|Scilex Holding Company - Revenue and Sales Volume|tevogen.com (TVGN) - Company Sales|ACOG: Revenue and Sales Volume|Company Total Revenue cogrx.com (CGTX)|Company Revenue Inhibikase|Cassava Pharma (SAVA) - Company Gross Revenue|Company Revenue Assertio Holdings, Inc. (ASRT)|coyatherapeutics.com - Company Sales Volume|Revenue and Sales Volume VTGN (Vistagen)|Ovid Therapeutics Inc (OVID) - Company Total Revenue|ABOS - Company Revenue|Company Sales Revenue CRVO (CervoMed Corporation)|ATHE (alteritytherapeutics.com) - Company Sales|CLNN (Clene) - Company Revenue|Company Revenue PepGen Inc|Company Sales Volume JUNS (jupiterneurosciences.com)|Revenue and Sales Volume RLMD|ANVS - Company Total Revenue|Grace Therapeutics - Company Sales|Revenue and Sales Volume fireflyneuro.com AIFF|KLTO - Company Revenue|Company Sales Revenue NRSN (NeuroSense Therapeutics)|Reviva Pharmaceuticals Holdings (RVPH) - Company Revenue|Company Total Revenue MetaVia (MTVA)|Company Revenue NeurAxis, Inc.|Company Sales Helius Medical Technologies Inc. (HSDT)|Revenue and Sales Volume PASG|Company Gross Revenue bionomics.com.au|Company Revenue Athira ATHA|ADXN: Company Sales Volume|Alzamend - Revenue and Sales Volume|Company Total Revenue Cyclerion Therapeutics|protagenic.com (PTIX) - Company Revenue|Pasithea Therapeutics Corp. - Company Sales Revenue|Company Sales CRGT|Company Revenue ATXI|Revenue and Sales Volume BCLI|Revenue and Sales Volume caratherapeutics.com (CARA)|Chromocell Therapeutics Corp. - Company Sales|Company Sales Revenue ELYM|ITCI - Company Revenue|LBPH (Longboard) - Company Sales Volume|MRNS: Revenue and Sales Volume|Company Total Revenue nkgenbiotech.com (NKGN)|Company Sales NRBO|Revenue and Sales Volume Sage Therapeutics Inc.|Company Revenue Neurotrope (SNPX)|TRVN (Trevena Inc) - Company Sales Revenue|Company Revenue Vigil Neuroscience, Inc. VIGL|Anew Medical Inc. (WENA) - Company Total Revenue|CERE - Company Revenue
